Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IQVIA to acquire Charles River drug discovery assets
The acquisition includes five sites specialising in various in vitro drug discovery services such as New Approach Methodologies (NAMs) and a small molecule AI platform. These assets are
The acquisition includes five sites specialising in various in vitro drug discovery services such as New Approach Methodologies (NAMs) and a small molecule AI platform. These assets are
Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered
The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio Pharmaceuticals (Guangdong). The company is headed by CEO and board director Gregory Oakes,
The partnership brings together a high-titre glutamine synthetase (GS) knockout (−/−) Chinese hamster ovary (CHO) cell line solution, free from additional intellectual property costs, aiming to streamline the
This marks a key development in the potential approval of adrabetadex, which could become a disease-modifying treatment for this rare paediatric neurodegenerative disorder. The FDA set 17 August
These facilities will integrate advanced manufacturing technologies and AI for supporting production of the company’s obesity and next-generation neuroscience medications. Construction is scheduled to commence in spring 2026,
The approval was granted by the US Food and Drug Administration (FDA) and follows positive AMPLIFY Phase III trial results. This trial enrolled patients from 2019 to 2021.
The submission targets adult patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer that has progressed after previous endocrine-based
The MoU with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), was signed at the
This partnership aims to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership programmes and facilitate the delivery of scientifically validated, partner-ready therapeutic candidates. It will combine Syngene’s